Methods	O
:	O

Trial	O
Design	O
and	O
Participants	O
:	O

It	O
is	O
an	O
open	O
label	O
,	O
randomized	O
clinical	O
trial	O
conducted	O
at	O
Bahria	O
International	O
Hospital	O
,	O
Lahore	O
,	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
combination	O
therapy	O
including	O
Dexamethasone	O
and	O
Aprepitant	O
in	O
hospitalized	O
patients	O
with	O
Covid	O
-	O
19	O
.	O

The	O
trial	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
principles	O
of	O
the	O

International	O
Conference	O
on	O
Harmonization	O
Good	O
Clinical	O
Practice	O
guidelines	O
and	O
approved	O
by	O
the	O

Bahria	O
International	O
Hospital	O
Ethic	O
Committee	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patients	O
.	O

Randomization	O
:	O

Case	O
report	O
form	O
included	O
demographics	O
,	O
major	O
comorbidities	O
,	O
medication	O
already	O
being	O
administered	O
.	O

Patients	O
were	O
divided	O
randomly	O
into	O
two	O
arms	O
Control	O
(	O
A	O
)	O
and	O
Interventioanl	O
(	O
B	O
)	O
.	O

Both	O
the	O
arms	O
received	O
routine	O
management	O
including	O
Dexamethasone	O
20mg	O
,	O
but	O
one	O
arm	O
received	O

Aprepitant	O
capsule	O
80mg	O
once	O
a	O
day	O
as	O
an	O
addition	O
for	O
3	O
-	O
5	O
days	O
depending	O
on	O
the	O
condition	O
of	O
patient	O
.	O

Inclusion	O
criteria	O
was	O
admitted	O
patients	O
above	O
18	O
years	O
,	O
both	O
genders	O
,	O
lab	O
confirmed	O
Covid	O
-	O
19	O
positive	O
based	O
on	O
PCR	O
,	O
more	O
than	O
72	O
hours	O
since	O
the	O
appearance	O
of	O
first	O
symptoms	O
.	O

Patients	O
with	O
moderate	O
to	O
critical	O
stages	O
were	O
included	O
.	O

Patients	O
with	O
respiratory	O
diseases	O
other	O
than	O
Covid	O
-	O
19	O
infection	O
and	O
pregnant	O
females	O
were	O
excluded	O
.	O

Primary	O
endpoint	O
was	O
total	B-PrimaryOutcome
in	I-PrimaryOutcome
hospital	I-PrimaryOutcome
days	I-PrimaryOutcome
and	O
the	O
duration	B-PrimaryOutcome
of	I-PrimaryOutcome
disease	I-PrimaryOutcome
.	O

Patients	O
and	O
care	O
givers	O
were	O
not	O
blinded	O
to	O
the	O
allocated	O
treatment	O
.	O

Lab	O
investigations	O
including	O
total	B-OtherOutcome
blood	I-OtherOutcome
cell	I-OtherOutcome
count	I-OtherOutcome
,	O
total	B-OtherOutcome
leukocyte	I-OtherOutcome
count	I-OtherOutcome
,	O
C	B-OtherOutcome
-	I-OtherOutcome
reactive	I-OtherOutcome
protein	I-OtherOutcome
,	O
D	B-OtherOutcome
-	I-OtherOutcome
dimers	I-OtherOutcome
,	O
lactate	B-OtherOutcome
dehydrogenase	I-OtherOutcome
,	O
oxygen	B-OtherOutcome
saturation	I-OtherOutcome
was	O
performed	O
on	O
daily	O
basis	O
to	O
monitor	O
the	O
status	O
of	O
patient	O
.	O

